* pregnant, lactating, or with intention to become pregnant during the study. * planned receipt of any investigational vaccine than the study intervention within 28 days before and after each study vaccination. * active covid-19 infection at the time of enrollment * history of allergic reactions or anaphylaxis to previous immunization or allergies to any components of the vaccines. * history of bleeding disorder, or prior history of significant bleeding or bruising following intramuscular injections or venipuncture (for the immunogenicity subset and hiv infected participants). * any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial or result in incomplete or poor quality data.

* pregnant, lactating, or with intention to become pregnant during the study. * planned receipt of any investigational vaccine than the study intervention within 28 days before and after each study vaccination. * active covid-19 infection at the time of enrollment * history of allergic reactions or anaphylaxis to previous immunization or allergies to any components of the vaccines. * history of bleeding disorder, or prior history of significant bleeding or bruising following intramuscular injections or venipuncture (for the immunogenicity subset and hiv infected participants). * any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial or result in incomplete or poor quality data.

- pregnant, lactating, or with intention to become pregnant during the study. - planned receipt of any investigational vaccine than the study intervention within 28 days before and after each study vaccination. - active covid-19 infection at the time of enrollment - history of allergic reactions or anaphylaxis to previous immunization or allergies to any components of the vaccines. - history of bleeding disorder, or prior history of significant bleeding or bruising following intramuscular injections or venipuncture (for the immunogenicity subset and hiv infected participants). - any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial or result in incomplete or poor quality data.

- pregnant, lactating, or with intention to become pregnant during the study. - planned receipt of any investigational vaccine than the study intervention within 28 days before and after each study vaccination. - active covid-19 infection at the time of enrollment - history of allergic reactions or anaphylaxis to previous immunization or allergies to any components of the vaccines. - history of bleeding disorder, or prior history of significant bleeding or bruising following intramuscular injections or venipuncture (for the immunogenicity subset and hiv infected participants). - any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial or result in incomplete or poor quality data.